SynOx Appoints New Board Chair as It Aims for TGCT Treatment Commercialization
Company - People | Apr 01, 2025 | Glide Healthcare (VC)
SynOx Therapeutics, a biopharmaceutical firm specializing in the development of emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), has announced a strategic leadership transition. Philip Astley-Sparke has been appointed as the new chair of the board, succeeding Ton Logtenberg, to guide SynOx's evolution into a globally focused entity. The company's priority now includes advancing its Phase 3 trial of emactuzumab, strategic regulatory filings, and enhancing commercial readiness. The new chair, Astley-Sparke, is a veteran biotechnology executive with a notable track record in clinical development and commercial launches, aiming to drive SynOx's successful market entry. SynOx, supported by Gilde Healthcare, Forbion, and other key investors, recently raised $92 million in Series B funding to support its commercialization and transatlantic expansion plans. In the context of TGCT, emactuzumab has demonstrated promising clinical efficacy and is also being studied for its potential in treating other macrophage-related diseases.
Sectors
- Biotechnology
- Venture Capital
- Healthcare
- Pharmaceuticals
Geography
- Ireland – SynOx Therapeutics is based in Dublin, Ireland, marking the geographical focus of the company.
- United Kingdom – The company's operations in Oxford signify its presence in the UK.
- United States – With SynOx expanding its US executive team and preparing for FDA interactions, the US is a significant market and regulatory milestone.
- Transatlantic (Europe and North America) – Gilde Healthcare operates in both Europe and North America, indicating the article's coverage of transatlantic business and investment.
Industry
- Biotechnology – The article centers around SynOx Therapeutics, a biotech firm developing emactuzumab, focusing on clinical-stage development and commercialization in biotechnology.
- Venture Capital – Gilde Healthcare and other investors participate in SynOx's funding, showcasing the role of venture capital in supporting biotech innovation.
- Healthcare – The focus on developing treatments for diseases like TGCT aligns the article with the healthcare industry.
- Pharmaceuticals – Emactuzumab development involves pharmaceutical research and trials, making this industry relevant to the article.
Financials
- $92 million – The amount raised by SynOx in its Series B funding round.
- $1.5 billion – Capital raised by Philip Astley-Sparke in prior roles.
- $1 billion – Value of BioVex Group Inc's acquisition by Amgen under Philip Astley-Sparke's leadership.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SynOx Therapeutics Limited | Target Company | Company | A late-stage clinical biopharmaceutical company developing emactuzumab. |
| Gilde Healthcare | Private Equity | Company | Investment firm backing SynOx Therapeutics, specializing in healthcare investments. |
| Philip Astley-Sparke | Board Chair | Person | Newly appointed board chair of SynOx Therapeutics with extensive biotech leadership experience. |
| Ton Logtenberg | Former Board Chair | Person | Preceding board chair who contributed to SynOx's growth. |
| Ray Barlow | CEO | Person | Chief Executive Officer of SynOx Therapeutics, involved in strategic direction. |
| Forbion, HealthCap, Bioqube Ventures, Medicxi | Investors | Company | Life science investors in SynOx Therapeutics, part of the funding syndicate. |
| Replimune Group Inc | Associated with Board Chair | Company | Company where Philip Astley-Sparke serves as Executive Chairman. |